Scholarlink

Metabolic bone disease (MBD) is a significant complication in intestinal failure (IF) patients on long-term parenteral nutrition (PN), leading to osteopenia, osteoporosis, and fractures. It results from nutritional deficiencies, calcium–phosphorus imbalances, metabolic acidosis, and PN-related factors. Diagnosis involves dual-energy X-ray absorptiometry (DEXA) scans and biochemical markers, while treatment focuses on lifestyle modifications, optimized PN composition, and pharmacological therapy. Bisphosphonates, parathyroid hormone (PTH) analogs, and denosumab help prevent bone loss but require careful monitoring. Regular screening and early intervention are essential to reduce complications, preserve bone density, and improve quality of life in PN-dependent patients.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Metabolic Bone Disease in Short Bowel Syndrome: Diagnosis and Management

  • 章节

  • 发表日期：

    2025年

查看全文
  • Ionuț Adrian Saizu,
  • Liana Gheorghe

摘要

Metabolic bone disease (MBD) is a significant complication in intestinal failure (IF) patients on long-term parenteral nutrition (PN), leading to osteopenia, osteoporosis, and fractures. It results from nutritional deficiencies, calcium–phosphorus imbalances, metabolic acidosis, and PN-related factors. Diagnosis involves dual-energy X-ray absorptiometry (DEXA) scans and biochemical markers, while treatment focuses on lifestyle modifications, optimized PN composition, and pharmacological therapy. Bisphosphonates, parathyroid hormone (PTH) analogs, and denosumab help prevent bone loss but require careful monitoring. Regular screening and early intervention are essential to reduce complications, preserve bone density, and improve quality of life in PN-dependent patients.